secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERPACE BIOSCIENCES, INC. (IDXG)
CIK:        0001054102
Form:       8-K
Filed at:   2022-08-15T23:59:59+00:00
Accession:  0001493152-22-022992
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Interpace Q2 revenue $9.4M (-16% YoY), net loss $3.9M on ThyGeNEXT price cut
----------------------------------------------------------------------------

- Q2 net revenue $9.4M, down 16% YoY; net loss $3.9M vs $3.4M prior year.
- Adjusted EBITDA $(2.9)M vs $(0.3)M; gross margin 37% vs 48% due to 70% retroactive ThyGeNEXT price cut.
- Cash balance fell to $1.9M at June 30 from $3.8M year ago; DSO improved 15% to 59 days.
- Launched Point2Glucose test; YTD net loss improved $1.5M to $(6.1)M; new thyroid data published.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1054102/000149315222022992/0001493152-22-022992-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1054102/000149315222022992/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-022992

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer